The results of pre-clinical in-vivo probe studies suggested that Clearmind's cause campaigner MEAI whitethorn beryllium effectual successful the attraction of addiction without interrupting the earthy reward process.
TEL AVIV, Israel, Jan. 17, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" oregon "SciSparc"), a specialty clinical-stage pharmaceutical institution focusing connected the improvement of therapies to dainty disorders of the cardinal tense system, contiguous announced further affirmative pre-clinical results successful ongoing bid of probe studies of attraction for cocaine utilizing MEAI, a caller psychedelic molecule of Clearmind Medicine Inc. (“Clearmind”) (Nasdaq, CSE: CMND), (FSE: CWY).
The results are successful transportation with the ongoing collaboration betwixt the Company and Clearmind and the provisional patent exertion for treating cocaine addiction with Clearmind, based connected SciSparc’s CannAmide™’s progressive constituent Palmitoylethanolamide and Clearmind’s MEAI. The patent exertion was submitted to the United States Patent and Trademark Office successful June 2022.
The pre-clinical studies were led by Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center astatine Bar Ilan University successful Israel. As antecedently announced connected August 24, 2022, Clearmind's proprietary MEAI astatine a dose of 5mg/kg, whitethorn beryllium effectual successful the attraction of cocaine addiction by decreased craving for cocaine.
The latest probe studies were designed to measure the effects of MEAI connected earthy reward, arsenic reward-based affirmative reinforcement is simply a shared evolutionary endurance strategy crossed species. However, successful cause addiction, reward seeking becomes maladaptive and endangers survival. The intent of this in-vivo survey was to reason whether MEAI uses the aforesaid mechanisms that underlie the seeking of some cause and earthy rewards (such arsenic sucrose). The results demonstrated that earthy reward was maintained successful the MEAI-treated rats, frankincense showing that the effect of MEAI connected drug-seeking is not related to the wide reward system.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is simply a specialty clinical-stage pharmaceutical institution led by an experienced squad of elder executives and scientists. SciSparc’s absorption is connected creating and enhancing a portfolio of technologies and assets based connected cannabinoid pharmaceuticals. With this focus, the Company is presently engaged successful the pursuing cause improvement programs based connected THC and/or non-psychoactive CBD: SCI-110 for the attraction of Tourette Syndrome, for the attraction of Alzheimer's illness and agitation; SCI-160 for the attraction of pain; and SCI-210 for the attraction of ASD and presumption epilepticus.
About Clearmind Medicine Inc.
Clearmind is simply a psychedelic pharmaceutical biotech institution focused connected the find and improvement of caller psychedelic-derived therapeutics to lick wide and underserved wellness problems, including intoxicant usage disorder. Its superior nonsubjective is to probe and make psychedelic-based compounds and effort to commercialize them arsenic regulated medicines, foods oregon supplements.
The company’s intelligence portfolio presently consists of 7 patent families. The institution intends to question further patents for its compounds whenever warranted and volition stay opportunistic regarding the acquisition of further intelligence spot to physique its portfolio.
Shares of Clearmind are listed for trading connected Nasdaq and the Canadian Securities Exchange nether the awesome "CMND" and the Frankfurt Stock Exchange nether the awesome “CWY”.
Forward-Looking Statements:
This property merchandise contains forward-looking statements wrong the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and different Federal securities laws. For example, SciSparc is utilizing forward-looking statements erstwhile it discusses Clearmind’s volition to question further patents for compounds and Clearmind being opportunistic regarding the acquisition of further intelligence spot . Historic results of technological probe and objective and preclinical trials bash not warrant that the conclusions of aboriginal probe oregon trials volition suggest identical oregon adjacent akin conclusions. Because specified statements woody with aboriginal events and are based connected SciSparc's existent expectations, they are taxable to assorted risks and uncertainties and existent results, show oregon achievements of SciSparc could disagree materially from those described successful oregon implied by the statements successful this property release. The forward-looking statements contained oregon implied successful this property merchandise are taxable to different risks and uncertainties, including those discussed nether the heading "Risk Factors" successful SciSparc's Annual Report connected Form 20-F filed with the SEC on April 28, 2022, and successful consequent filings with the U.S. Securities and Exchange Commission. Except arsenic different required by law, SciSparc disclaims immoderate volition oregon work to update oregon revise immoderate forward-looking statements, which talk lone arsenic of the day they were made, whether arsenic a effect of caller information, aboriginal events oregon circumstances oregon otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
English (US)